Teva

Neurim Pharmaceutical and Teva Pharmaceutical Industries Ltd agreed That Teva will in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia in Israel and become a stratgic partner. Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.

With more than a century of experience in the healthcare industry, the Company enjoys a firmly established international presence, operating through a carefully tailored network of worldwide subsidiaries. Headquartered in Israel, above 80% of Teva's sales, which totaled US$11.1 billion in 2008, are in North America and Europe. Teva has over 38,000 employees worldwide and production facilities in Israel, North America, Europe and Latin America.

For further information, please visit www.tevapharm.com

 

Lundbeck

Neurim Pharmaceuticals Ltd  and H. Lundbeck A/S announced that Lundbeck in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia for the majority of markets in Europe including the five major markets. Furthermore, Lundbeck holds the exclusive option to evaluate commercialization in markets outside of Europe.

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company’s revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com

Nycomed will be marketing Circadin® in Belgium, Netherlands, Austria, Greece, the Baltic States, Norway, Sweden, Finland, Denmark, Iceland, Switzerland, Luxembourg and Russia-CIS. The first launch is expected during fourth quarter 2007

Nycomed provides products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.

Privately owned, the combined group had non-audited estimated annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results).
For more information visit www.nycomed.com